A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

Bertrand Tombal, Fred Saad, Enrique Gallardo, Andrey Soares, Yohann Loriot, Ray McDermott, Erik Briers, Mikael Lagström, Corneel Coens, Coralie Poncet, Beatrice Fournier, Silke Gillessen

Open source

DOI: 10.1080/14796694.2025.2592722
Published: 2025-11-28
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2592722,
  title = {A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases},
  author = {Bertrand Tombal and Fred Saad and Enrique Gallardo and Andrey Soares and Yohann Loriot and Ray McDermott and Erik Briers and Mikael Lagström and Corneel Coens and Coralie Poncet and Beatrice Fournier and Silke Gillessen},
  year = {2025},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2025.2592722},
  url = {https://doi.org/10.1080/14796694.2025.2592722}
}

RIS

TY  - JOUR
TI  - A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases
AU  - Bertrand Tombal
AU  - Fred Saad
AU  - Enrique Gallardo
AU  - Andrey Soares
AU  - Yohann Loriot
AU  - Ray McDermott
AU  - Erik Briers
AU  - Mikael Lagström
AU  - Corneel Coens
AU  - Coralie Poncet
AU  - Beatrice Fournier
AU  - Silke Gillessen
PY  - 2025
JO  - Future Oncology
DO  - 10.1080/14796694.2025.2592722
UR  - https://doi.org/10.1080/14796694.2025.2592722
ER  -

APA

Tombal, B., Saad, F., Gallardo, E., Soares, A., Loriot, Y., McDermott, R., Briers, E., Lagström, M., Coens, C., Poncet, C., Fournier, B., & Gillessen, S. (2025). A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. Future Oncology. https://doi.org/10.1080/14796694.2025.2592722

Source records

crossref · retrieved 2026-09-26T10:12:49.535Z